ES8405032A1 - Un procedimiento para preparar compuestos de inclusion de antibioticos del grupo de la lankacidina con ciclodextrina. - Google Patents

Un procedimiento para preparar compuestos de inclusion de antibioticos del grupo de la lankacidina con ciclodextrina.

Info

Publication number
ES8405032A1
ES8405032A1 ES521362A ES521362A ES8405032A1 ES 8405032 A1 ES8405032 A1 ES 8405032A1 ES 521362 A ES521362 A ES 521362A ES 521362 A ES521362 A ES 521362A ES 8405032 A1 ES8405032 A1 ES 8405032A1
Authority
ES
Spain
Prior art keywords
lankacidin
inclusion compound
group antibiotic
antibiotic
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES521362A
Other languages
English (en)
Spanish (es)
Other versions
ES521362A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of ES521362A0 publication Critical patent/ES521362A0/es
Publication of ES8405032A1 publication Critical patent/ES8405032A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES521362A 1982-04-12 1983-04-11 Un procedimiento para preparar compuestos de inclusion de antibioticos del grupo de la lankacidina con ciclodextrina. Expired ES8405032A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57061343A JPS58177949A (ja) 1982-04-12 1982-04-12 ランカシジン群抗生物質包接化合物

Publications (2)

Publication Number Publication Date
ES521362A0 ES521362A0 (es) 1984-05-16
ES8405032A1 true ES8405032A1 (es) 1984-05-16

Family

ID=13168385

Family Applications (1)

Application Number Title Priority Date Filing Date
ES521362A Expired ES8405032A1 (es) 1982-04-12 1983-04-11 Un procedimiento para preparar compuestos de inclusion de antibioticos del grupo de la lankacidina con ciclodextrina.

Country Status (8)

Country Link
US (1) US4497803A (enExample)
EP (1) EP0091782B1 (enExample)
JP (1) JPS58177949A (enExample)
CA (1) CA1216581A (enExample)
DE (1) DE3372577D1 (enExample)
DK (1) DK158883A (enExample)
ES (1) ES8405032A1 (enExample)
ZA (1) ZA832471B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0094157B1 (en) * 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its use
HU196230B (en) * 1983-12-29 1988-10-28 Chinoin Gyogyszer Es Vegyeszet Process for producing water-soluble forms of polyene antibiotics and pharmaceutics comprising such active ingredient and plant protective with antifungal effect
US4616008A (en) * 1984-05-02 1986-10-07 Takeda Chemical Industries, Ltd. Antibacterial solid composition for oral administration
US4883785A (en) * 1984-07-27 1989-11-28 Chow Wing Sun Complex of anti-fungal agent and cyclodextrin and method
JPS61207380A (ja) * 1985-03-11 1986-09-13 Taiyo Yakuhin Kogyo Kk モベンゾキサミンの経口製剤
US4914206A (en) * 1985-10-06 1990-04-03 Takeda Chemical Industries, Ltd. Lankacidin derivatives and production thereof
ES2058057T3 (es) * 1985-12-05 1994-11-01 Takeda Chemical Industries Ltd Derivados de lancacidina y su produccion.
US4885275A (en) * 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
MY106598A (en) * 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AT400674B (de) * 1991-07-24 1996-02-26 Biochemie Gmbh Pharmazeutische pleuromutilin-zubereitung
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
CA2276306C (en) * 1996-12-30 2009-12-15 The Johns Hopkins University School Of Medicine Loss of imprinting-based in vitro diagnostic method to determine the propensity to develop cancer
EP1332756A3 (en) * 1996-12-30 2003-12-10 The Johns Hopkins University School Of Medicine Compositions and methods for restoring a normal pattern of imprinting to cells
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
US6818662B2 (en) * 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
ES2584183T3 (es) * 2003-03-28 2016-09-26 Ares Trading S.A. Formulaciones de cladribina para suministro mejorado oral y transmucosa
WO2004087101A2 (en) * 2003-03-28 2004-10-14 Ivax Corporation Oral formulations of cladribine
UA81305C2 (en) 2003-07-02 2007-12-25 Ares Trading Sa Formulation of cladribine (variants), cladribine-cyclodextrin complex, use of cladribine-cyclodextrin complex, mixture
US7655442B2 (en) 2004-01-29 2010-02-02 Eisai R&D Management Co., Ltd. Method for stabilizing macrolide compounds
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009532A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010466A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US8845627B2 (en) 2008-08-22 2014-09-30 Boston Scientific Scimed, Inc. Regulating pressure to lower temperature in a cryotherapy balloon catheter

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2959580A (en) * 1956-10-17 1960-11-08 Univ Minnesota Formation of inclusion compounds
JPS4810442B1 (enExample) * 1968-10-26 1973-04-03
US3869443A (en) * 1971-02-25 1975-03-04 Sterling Drug Inc N,N{40 -Heptamethylenebis(4-trifluoromethoxybenzamide)-{62 -cyclodextrin inclusion complex
JPS5738569B2 (enExample) * 1974-03-27 1982-08-16
HU176215B (en) * 1978-01-27 1981-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1
US4407795A (en) * 1981-07-16 1983-10-04 American Cyanamid Company Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use

Also Published As

Publication number Publication date
ES521362A0 (es) 1984-05-16
JPS58177949A (ja) 1983-10-18
EP0091782A3 (en) 1984-09-26
ZA832471B (en) 1983-12-28
DK158883D0 (da) 1983-04-11
EP0091782B1 (en) 1987-07-22
CA1216581A (en) 1987-01-13
DE3372577D1 (en) 1987-08-27
JPH0336827B2 (enExample) 1991-06-03
US4497803A (en) 1985-02-05
DK158883A (da) 1983-10-13
EP0091782A2 (en) 1983-10-19

Similar Documents

Publication Publication Date Title
ES455894A1 (es) Procedimiento de secado de las soluciones que contienen aci-do borico.
AU562068B2 (en) Agent for retarding polymerization of aziridine compounds
ES8706443A1 (es) Un procedimiento para preparar una solucion parenteral de activador de plasminogeno de tejido (t-pa)
ES8306767A1 (es) "metodo de preparar compuestos esteroidicos antiinflamatorios".
ES412365A1 (es) Procedimiento para preparar asfalto con una composicion te-niendo elevada fuerza de adherencia.
ES399984A1 (es) Procedimiento para la eliminacion de desechos por via bio- logica.
AU586169B2 (en) Moulding material and process for its preparation
EP0212837A3 (en) Deodorizing agent
ES479476A1 (es) Procedimiento para la obtencion de celulosa.
ES448793A1 (es) Procedimiento para la produccion de cerillas de friccion.
JPS5358589A (en) Pullulan aminoalkyl ether
CA1024732A (en) Additive for reducing gel strength in aqueous drilling fluids
ES462987A1 (es) Un procedimiento para la obtencion de 2-furil-(3,4-dimetil-2-piridil)-carbinol.
SU1341767A1 (ru) Способ получения йодинола
IE811005L (en) Solvate of amoxicillin
JPS5394348A (en) Adhesive
GB1496120A (en) 3-(10-undecenyloxy)propionitrile
KR830006215A (ko) 4-저급알킬-3-페녹시피리딘-1-옥사이드의 제조방법
JPS51149348A (en) Gel composition
JPS5222079A (en) Modification of cellulose
ES438725A1 (es) Un procedimiento de preparacion de derivados sustituidos del acido prostanoico.
SE8305615D0 (sv) Bindemedelskomposition
AU3378689A (en) New acrylic derivative of urea
CH612907A5 (en) Process for the preparation of a new 1-aryloxy-4-amino-2-butanol
GB794417A (en) Improvements in octahydronaphthalene derivatives, compositions of matter containing said derivatives and their process of preparation

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19971201